1 completed, 1 recruiting. 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Completed 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Muscular Dystrophy, Duchenne and Becker Types: new trials by email Literature Review of Muscular Dystrophy, Duchenne and Becker Types trials Research Report on Muscular Dystrophy, Duchenne and Becker Types
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO) Zeleciment Rostudirsen (DYNE-251), Placebo - Duchenne Muscular Dystrophy (DMD), Muscular Dystrophy, Duchenne | Phase 3 | Recruiting | Dyne Therapeutics | 90 | 2026-06-01 | 2026-05-27 |
| Effectiveness of a Multimodal Physiotherapy Program With Virtual Reality Glasses in Duchenne and Becker. multimodal physiotherapy program with RV, traditional physiotherapy program - Muscular Dystrophy, Duchenne and Becker Types | Not applicable | Completed | University of Malaga | 12 | 2021-03-15 | 2024-05-13 |
Muscular Dystrophy, Duchenne (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Genetic Diseases, X-Linked (1) · Muscular Dystrophies (1) · Myotonic Dystrophy (1) · Neuromuscular Diseases (1)
Muscular Diseases (2) · Muscular Disorders, Atrophic (2) · Musculoskeletal Diseases (2) · Nervous System Diseases (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Genetic Diseases, X-Linked (1) · Heredodegenerative Disorders, Nervous System (1) · Muscular Dystrophies (1) · Myotonic Disorders (1) · Neurodegenerative Diseases (1) · Neuromuscular Diseases (1)
Dyne Therapeutics (1) · University of Malaga (1)
Spain (1) · United States (1)
Maria Teresa Labajos Manzanares, PhD (1)
2025 (1)